KIT and melanoma: Overall, by affecting the expression levels of both KIT and BCL-2 proteins and, consequently, by impinging on MAPK and PI3K/AKT pathways, as well as on the balance between pro-death and pro-survival factors, our compound may be used to interfere with oncogene expression in melanoma cells.